Esophageal Cancer Molecular Diagnostics Market Regional Analysis:
APAC Market Insights
Asia Pacific industry is likely to dominate majority revenue share of 60% by 2035. The market growth in the region is also expected on account of a lack of awareness of the symptoms and a lifestyle that causes high inflammation in the body. In many of these countries, access to good healthcare is limited. Along with uninhibited use of tobacco, and alcohol, low income, and various vitamin deficiencies, the inhabitants face an increased risk of oesophageal cancer.
In China, the market is expanding meteorically, to suppress the alarming mortality rates of oesophageal cancer. These developments result in a bigger space for the esophageal cancer molecular diagnostics market to grow. Korea has seen a significant development in diagnosing esophageal cancers early for a better prognosis and is expected to further rely on diagnostics technology to shrink the mortality percentage further
North America Market Insights
By the end of 2035, North American esophageal cancer molecular diagnostics market is predicted to capture around 20% share owing to the increasing frequency of obesity and high alcohol use in the region. Barret’s oesophagus is also a risk factor that will increase the cases of oesophageal cancer in the region, specifically in North America. The government here is doubling its investments in healthcare with the latest innovations in the field of medicine. It encourages people to get better healthcare and diagnosis early.
Top market players are expected to invest in technological advancements to increase early diagnosis. Better diagnostics lead to an increase in the number of oesophageal cancers, which are mostly diagnosed in the advanced stages. More common in Caucasians, it accounts for 2% of the cause of death in North America. One can expect moderate growth in revenue in this area.
